Lynn Karlijn Debels

Lynn Karlijn Debels

Auto-generated profile, based on publicly available information

Lynn Karlijn Debels

UZ Brussel, Belgium

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2025 in Endoscopy
Verified
Journal Article
Closed access
PDF file
DTDavid J Tate
David J Tate
ESEnrique Rodriguez de Santiago
Enrique Rodriguez de Santiago
IGIan M. Gralnek∗
Ian M. Gralnek∗
TTTony C. Tham
Tony C. Tham
MMMichele Montori
Michele Montori
RSRoy M. Soetikno
Roy M. Soetikno
1 A POEM equipment checklist should be used before commencing the procedure to ensure the availability and proper functioning of all necessary materials. 2 A thorough esophageal cleansing before mucosal incision is mandatory. There should be no residual dietary liquid or food in the lumen. 3 Use at least 5–10 mL of lifting agent, which should be injected using a needle at the desired point where the mucosotomy will commence. 4 To create the mucosotomy, the first incision should be made at the site of previous injection with the fewest possible taps on the electrosurgical unit using a cutting mode, with the knife tip at 45–80° to the mucosal surface. 5 After adequate submucosal injection (through a needle or knife), the incision should be extended by 1.5–2 cm in the longitudinal axis from cranial to caudal, in the planned direction of the tunnel. 6 Dissection within the tunnel should be performed using sequential injection of saline and chromic dye (if available using the knife jet function) and dissection with the knife. Pushing the endoscope forward gently against the advancing submucosa–muscularis propria interface is important to facilitate mucosal tunneling. 7 The myotomy should be performed in a cranial to caudal manner, starting 2 cm or more below the caudal extent of the mucosotomy site. 8 ESGE recommends that the myotomy should be extended 2–3 cm distal to the gastroesophageal junction to allow complete disruption of the lower esophageal sphincter. 9 ESGE recommends that POEM can be performed on either the anterior (1–2 o’clock in supine position) or posterior (5–6 o’clock) side. 10 ESGE recommends that the myotomy length should be tailored to the disease being treated, with evidence favoring short esophageal-side myotomy if indicated because of decreased adverse events and procedure times. 11 ESGE recommends the use of through-the-scope clips for mucosal closure owing to their high efficacy and availability, and lower price compared with other closure methods. 12 Mucosal injury during POEM should be proactively sought during the procedure and particularly before completion. Mucosal injury can be represented on a spectrum from whitening of the overlying mucosa to a full-thickness perforation. 13 ESGE recommends performing POEM using low flow CO2 insufflation. 14 In the absence of adverse events, resume fluids on day 1, soft diet on day 3, and normal diet on day 7 post-POEM. 15 ESGE recommends against the routine use of standard or computed tomography fluoroscopic esophagrams after POEM in asymptomatic patients. ‡ joint first co-authorship. * joint senior authors. Article published online: 28 May 2025 © 2025. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

10 June 2025 in Endoscopy
Verified
Journal Article
Closed access
PDF file
Maria Eva ArgenzianoMaria Eva Argenziano
Maria Eva Argenziano
ASAndrea Sorge
Andrea Sorge
MMMichele Montori
Michele Montori
PPPieter Jan Poortmans
Pieter Jan Poortmans
SSSander Smeets
Sander Smeets
DTDavid J Tate
David J Tate
This study aimed to determine the accuracy of the muscle-retracting sign (MRS) for the detection of deep submucosal invasion (SMI) in early rectal cancer. In this prospective observational single-center study, consecutive rectal lesions that underwent endoscopic resection using the pocket-detection method (PDM) between August 2023 and March 2025 were included. Directionality of the initial submucosal dissection targeted any morphologic or surface vascular pattern at risk of deep SMI to attempt MRS identification. Histopathology was the reference standard for MRS diagnostic accuracy in detecting deep SMI. 38 rectal lesions (median size 30 mm [interquartile range 20]) were included. The PDM for detection of the MRS was successful in all cases, with MRS positivity in 15/38 cases (39.5%). Deep SMI was confirmed in 15/38 cases (39.5%). The accuracy of MRS positivity for deep SMI detection was 84.2% (95%CI 69.6%–92.6%), with a sensitivity of 80.0% (95%CI 54.8%–92.9%), specificity of 87.0% (95%CI 67.9%–95.5%), positive likelihood ratio of 6.13, negative likelihood ratio of 0.23, and area under the receiver operating characteristic curve of 0.83 (95%CI 0.71–0.96). The rate of R0 resection was 92.1% (35/38). The MRS detected using the PDM demonstrated moderate-to-high accuracy for the prediction of deep SMI in early rectal cancer. This finding may allow the precise selection of an endoscopic resection strategy based on invasion depth for the minimally invasive treatment of early rectal cancer.

13 May 2026 in Endoscopy
Verified
Journal Article
Closed access
PDF file
IGIan M. Gralnek
Ian M. Gralnek
JMJohn Morris
John Morris
Stig Borbjerg LaursenStig Borbjerg Laursen
Stig Borbjerg Laursen
MCMarine Camus
Marine Camus
GTGeorgios Tziatzios
Georgios Tziatzios
TTTony C. Tham
Tony C. Tham
This guideline is an update of the 2021 ESGE Guideline on Endoscopic diagnosis and management of nonvariceal upper gastrointestinal hemorrhage. The following are the new and/or revised recommendations. 1 ESGE does not recommend the routine use of video capsule endoscopy or telemetric blood-sensing capsules in the management of patients with suspected upper gastrointestinal hemorrhage (UGIH). 2 ESGE suggests, if intravenous erythromycin is unavailable, pre-endoscopy administration of intravenous metoclopramide in selected patients with clinically severe or ongoing active UGIH. 3 ESGE suggests that pre-endoscopy high dose intravenous proton pump inhibitor (PPI) therapy be considered in patients presenting with acute UGIH; however, this should not delay early endoscopy. 4 ESGE does not recommend emergent (≤6 hours) or urgent (≤12 hours) upper GI endoscopy unless the patient remains hemodynamically unstable despite adequate resuscitation. 5 ESGE suggests that patients with peptic ulcers presenting with an adherent clot (Forrest IIb) should undergo endoscopic therapy, with clot removal and subsequent endoscopic hemostasis if indicated, provided that the endoscopist has the technical competence to safely remove the clot and manage potential conversion to a higher risk bleeding lesion. 6 ESGE could not reach a consensus for or against the routine use of a Doppler endoscopic probe in treatment decisions of high risk endoscopic stigmata of peptic ulcer bleeding. 7 ESGE suggests the use of over-the-scope (OTS) clips as monotherapy as an alternative to combination therapy as first-line therapy for peptic ulcer bleeding with high risk stigmata (FIa, FIb) owing to a lower risk of further bleeding compared with standard endoscopic hemostatic therapy. 8 ESGE recommends, for patients with an ulcer with a nonbleeding visible vessel (FIIa), contact or noncontact thermal therapy, mechanical therapy (e.g. through-the-scope or OTS clips), or injection of a sclerosing agent, each as monotherapy or in combination with epinephrine injection. 9 ESGE suggests, for patients with an ulcer with a nonbleeding visible vessel (FIIa), OTS clips may be used as alternative monotherapy. 10 ESGE suggests hemostatic forceps with soft coagulation may be used as monotherapy in the treatment of peptic ulcer bleeding with high risk stigmata (FIa, FIb, and FIIa). 11 ESGE suggests that hemostatic agents should not be used as monotherapy in the first-line treatment of patients with high risk stigmata of peptic ulcer bleeding. 12 ESGE suggests that, in patients with persistent bleeding refractory to standard hemostasis modalities, the use of a topical hemostatic agent or OTS clips should be considered. 13 ESGE recommends that, in patients with persistent bleeding refractory to all modalities of endoscopic hemostasis, including topical hemostatic agents and OTS clips, transcatheter angiographic embolization (TAE) should be considered. Surgery is indicated when TAE is not locally available or after unsuccessful TAE. 14 ESGE suggests that prophylactic TAE be considered in selected high risk cases of peptic ulcer bleeding (e.g. patients with hemodynamic instability at presentation, posterior duodenal wall ulcer location, large ulcer size [>2 cm], or when durable endoscopic hemostasis is considered uncertain). 15 ESGE could not reach a consensus for or against the routine use of potassium-competitive acid blockers for patients who have undergone endoscopic hemostasis. 16 ESGE recommends that, for patients with clinical evidence of recurrent peptic ulcer bleeding, use of an OTS clip should be considered. Should this second attempt at endoscopic hemostasis also be unsuccessful, TAE should be considered. Surgery is indicated when TAE is either locally unavailable or after unsuccessful TAE. 17 ESGE recommends that, in patients with peptic ulcer hemorrhage who require ongoing anticoagulation therapy, anticoagulation should be resumed as soon as clinically indicated based on thromboembolic risk. 18 ESGE suggests that iron therapy be initiated prior to hospital discharge in patients with peptic ulcer bleeding and iron deficiency and/or anemia. 19 ESGE suggests that early oral nutrition, within 24 hours following endoscopic hemostasis, be initiated in patients with peptic ulcer bleeding in whom durable hemostasis has been achieved.

22 May 2026 in Endoscopy
Verified
Journal Article
Closed access
IGIan M. Gralnek
Ian M. Gralnek
JMJohn Morris
John Morris
Stig Borbjerg LaursenStig Borbjerg Laursen
Stig Borbjerg Laursen
MCMarine Camus
Marine Camus
GTGeorgios Tziatzios
Georgios Tziatzios
TTTony C. Tham
Tony C. Tham

14 March 2025 in Endoscopy
Verified
Journal Article
Closed access
PDF file
SSSander Smeets
Sander Smeets
MAMaria Eva Argenziano
Maria Eva Argenziano
ACAlexander C. De Crem
Alexander C. De Crem
LDLobke Desomer
Lobke Desomer
JAJohn Anderson
John Anderson
DTDavid J Tate
David J Tate
Background Colorectal polypectomy is operator dependent, with variable rates of complete resection. The currently available assessment tools do not provide specific competency-based evaluation of provider technique. We aimed to validate the Global Polypectomy Assessment Tool (GPAT), a novel competency assessment tool for colorectal polypectomy. Methods GPAT was derived from the ESGE Curriculum for Training in endoscopic mucosal resection in the colon. Members of the curriculum taskforce plus three invited trainees and three medical students (collectively: the assessors) anonymously assessed nine endoscopic-view only polypectomy videos. The primary end point was the correlation of the assessors’ GPAT scores with a consensus-derived reference GPAT score per video. Secondary end points were the assessors’ subjective impression versus their GPAT score and interobserver agreement among assessors’ GPAT scores. Results 171 GPAT assessments by 19 assessors (consultant gastroenterologists [n = 10], trainee gastroenterologists [n = 4], consultant surgeons [n = 2], and medical students [n = 3]) were analyzed. Reference GPAT scores did not differ significantly from those of the assessors (73.1 % [95 %CI 64.6 %–81.6 %] vs. 69.3 % [95 %CI 64.9 %–81.2 %]; P = 0.47). There was moderate IOA in GPAT scores among gastroenterologists (intraclass correlation coefficient [ICC], 0.52 [moderate]) but not among nongastroenterologists (ICC 0.32 [poor]). GPAT correlated with assessors’ subjective impression of polypectomy quality (correlation coefficient 0.98 [95 %CI 0.90–1.00]; P < 0.001). Overall assessors’ qualitative usability scoring of GPAT was positive. Conclusions GPAT allows standardized scoring of polypectomies, with moderate IOA among gastroenterologists and correlation with subjective impressions of polypectomy quality. GPAT could standardize assessment of trainee polypectomy competency offering structured feedback on performance. ‡ Joint first authors Article published online: 14 March 2025 © 2025. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

3 March 2025 in Frontline Gastroenterology
Verified
Journal Article
Closed access
PDF file
LDLynn K Debels
Lynn K Debels
ASAndrea Sorge
Andrea Sorge
MAMaria Eva Argenziano
Maria Eva Argenziano
VLVikash Lala
Vikash Lala
MMMichele Montori
Michele Montori
DTDavid J Tate
David J Tate
Objective Operator technical skill is recognised as a critical determinant of surgical outcomes. However, no equivalent recognition for quality of endoscope tip manipulation (tip-control) exists. We aimed to create an ex-vivo snare tip soft coagulation (STSC) model to objectively quantify endoscopist tip-control. Method This prospective interventional study was conducted at Ghent University Hospital. Participants applied STSC to a training model simulating four endoscopic mucosal resection (EMR) defects on a slice of ham. Accuracy (correct/total-hits) and speed (correct-hits/s) were assessed from a video by a single-blinded rater using a web-based scoring system. Results 22 endoscopists participated. Interventional endoscopists demonstrated significantly higher accuracy (87.0%) and speed (0.184 correct-hits/s) compared with trainees (74.5%, 0.106 correct-hits/s; both p<0.001) and non-interventional consultants (77%, 0.141 correct-hits/s; p5 years of endoscopic experience did not have better tip-control (accuracy 88.0%(p=0.07), speed 0.132 hits/s (p=0.36)) when compared with those with ≤4 years of experience. Conclusion This inexpensive ex vivo STSC simulation model effectively quantified endoscopic tip-control, correlating with endoscopist expertise and clinical profiles. The model could support the shift towards competency-based education, potentially improving patient outcomes. Trial registration number NCT05660317.